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This investigation aims to analyze the profile of long-term evolution of rheumatic fever
in children and adolescents and outcomes after the control of recurrences. The cohort
involved 702 patients followed from 1.3 to 16.9 years covering the two periods, before and
after the implementation of a prevention program. Besides the establishment of the Refer-
ence Center in the State of Minas Gerais and the implementation of strategies to promote
the compliance to prophylaxis, a project for education of health professionals was carried
out in 23 cities. In addition to the clinical and epidemiological profile, the severity of the
disease was analyzed. Mixed lesions were found in 27.1%, valvar regurgitation in 72.9%,
and complete regression of the valvar lesions was seen in 34.4% of the patients, mostly
presenting mild dysfunctions. The recurrence rate per patient-year was 0.058 and out of a
total of 85 recurrences, 21.4% occurred in the first and 7.5% in the second period. More
severe degrees of carditis and significant valvar sequels presented a higher prevalence in
patients with recurrences. The comparative analysis between the two periods showed no
changes regarding the age at the primary attack, gender, type, and site of valvar lesions and
affected joints; however, important modifications in the indices of severity were observed
after the control of recurrences. A significant decrease in the prevalence of severe cardi-
tis, obstructive valvar sequels, hospital admissions, surgical approach, and deaths was
seen. This investigation showed that although the clinical profile of presentation remains
unchanged, the control of repeated attacks can improve the morbimortality rates. In this
context, the secondary prophylaxis should be the first priority in the control of the disease
in developing countries, taking into account the difficulties found for effective primordial
and primary prevention.
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INTRODUCTION
Rheumatic fever (RF) and its more serious consequence, the
rheumatic heart disease (RHD), continue to pose a significant
problem in several parts of the world. Although the incidence
of the disease in developed areas have markedly declined after
the 1950s, RHD remains the leading cause of acquired cardiac
disease in developing countries among patients aged from 5 to
30 years (1, 2). On a global scale, and considering all age groups,
an estimated 15.6–19.6 million people suffer from RHD (3). As a
result of a disability acquired at an early age, valvar sequels can
be carried throughout life and account for increased rates of hos-
pitalization, surgery, and death. In this setting, an estimated 6.6
million disability-adjusted life years are lost yearly to the disease
worldwide (4). The socioeconomic factors involving considerable
personal and collective costs constitute important determinants of
the disease burden. Maternal low education level has been asso-
ciated with recurrent attacks and identified as an independent
risk factor for significant chronic valvar disease (5). Environmen-
tal factors, mainly poor housing and overcrowding, must also be
included in this context (1, 4).
More recently, large-scale echocardiographic screenings have
shown a prevalence of RHD much higher than previously thought,
ranging from 5 to 10-fold when compared to auscultation (6–13).
It is a fact that some patients develop RHD, but the clinical history
of previous acute episodes can go unnoticed due to poor access to
health services or the presence of mild or subclinical valvar lesions.
This scenario of underdiagnosis is worrying as without prevention
of recurrences, the risks of more advanced disease are considerable.
On the other hand, the overdiagnosis results in the undesirable
exposure of non-rheumatic patients to the rigors of prophylaxis.
Thus, an accurate diagnosis is essential to make adequate decisions
in both directions. The international echocardiographic criteria
for the diagnosis of RHD, recently established by the World Heart
Federation, have given a very important contribution to diagnos-
tic accuracy, mainly to the identification of patients without a past
history of RF (14).
The magnitude of the valvular sequels has been associated with
the degree of cardiac involvement during the acute phase (15–
17). Additionally, as it has long been noticed, the valve deformity
can be progressive even in the absence of recurrences as a result
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from the process of cicatrization (18, 19). Nonetheless, repeated
acute attacks play an important role in the unfavorable evolution
and severity of RHD. Considering this potential evolution, it is a
fact that there is no curative therapy. After the establishment of
valvular damage, any treatment, clinical or surgical, is palliative
(20). Faced with our limitations in the therapeutic approach of
patients with RF and RHD, continuing attention must be given to
the primary and secondary prophylaxis. The prompt introduction
of an effective secondary prophylaxis can avoid the worsening of
preexisting valvar dysfunctions or the appearance of new lesions
related to the subsequent acute episodes. In areas where the disease
is prevalent, control programs require investments. Strategies are
needed to implement the adherence of patients to the regimes of
secondary prophylaxis to avoid recurrences.
This investigation aims to analyze the profile of long-term evo-
lution of patients with rheumatic valvar lesions and the outcomes
after the control of recurrences, which followed the implementa-
tion of the Prevention Program for Rheumatic Fever-UFMG.
MATERIALS AND METHODS
STUDY POPULATION AND DATA COLLECTION
This investigation enrolled 702 children and adolescents with
diagnosis of RF based on the revised Jones criteria (21). The
patients were consecutively attended from July 1977 to Febru-
ary 2000 at the Division of Pediatric Cardiology/Hospital das
Clínicas-UFMG and were followed by the same team of pedi-
atric cardiologists over a period ranging from 1.3 to 16.9 years
(mean= 6.8± 2.6 years). The age at admission ranged from 2.6 to
19.9 years (mean: 10.3± 3.1 years; median 9.8 years).
Outpatients and inpatients databases, records, and referring
reports from the local health centers were retrospectively investi-
gated for all patients with the diagnosis of RF, acute or chronic
phase. Information was sought in the past history, first clini-
cal evaluation, and follow-up, besides electrocardiogram, chest
roentgenogram, and echocardiogram records.
PROGRAM DESIGN AND STRATEGIES
The patients were referred during the acute or chronic phases of
the disease to the Division of Pediatric Cardiology-UFMG which,
in 1986, established the Prevention Program for Rheumatic Fever-
UFMG. Since 1988, the university hospital has been the Reference
Center in Minas Gerais, a Brazilian state with 0.59 million km2, 853
municipalities, and 19.6 million inhabitants. As part of the pro-
gram, health professional education was carried out in the capital
and other 22 cities of the state, grouped by regions and supported
by local coordinators. The initiative also included distribution
of educational material, promotion of scientific events, and was
preceded by divulgation in the printed and electronic media.
The activities of the program were integrated into the existing
public health infrastructure, and the following strategies have been
adopted to assist patients at the Reference Center for Rheumatic
Fever since 1988: the establishment of the Rheumatic Fever Out-
patients Clinic at the university hospital; introduction of protocols
for standardized approach to diagnosis and management; medical
care and orientation provided by a multidisciplinary team; special
attention to promote health education for patients and families;
appointments for first visits demanded by the public healthcare
state system were centralized and organized by the Health Sec-
retary; transportation for patients and parents provided; routine
clinical follow-up no longer than at every 6 months; besides the
laboratorial exams demanded by clinical evaluation, routine inves-
tigation of ASO titer at 6 months’ interval for all patients; echocar-
diographic screening for all definitive or suspected cases of RF
or RHD, even those without clinical evidence of cardiac dam-
age; reporting back to referring health centers to support the local
follow-up of patients; distribution of free medication; secondary
prophylaxis regimens with intramuscular benzathine penicillin
injections at 21 days’ interval; introduction of a prophylaxis card
to control the compliance; active search for missing patients and
accommodation at the university hospital for inpatients’ parents.
DATA ANALYSIS
Demographical, clinical, and epidemiological data were assembled
and patients were divided into two groups according to the period
of admission: before and after the establishment of the program,
from July 1977 to July 1988 and from August 1988 to February
2000, respectively. The degree of carditis and valvular sequels was
classified as mild,moderate,and severe according to the established
criteria on the protocol for medical assistance (18). Moderate to
severe and severe degrees of cardiac involvement for both acute
and chronic phases were classified as significant. The characteri-
zation of an established RHD was defined at least 1 year after the
acute phase. The last clinical and laboratorial evaluations in each
respective period of investigation were considered for the charac-
terization of the disease. Variables were summarized as percentage,
and categorical variables were compared using Fisher exact test or
Pearson’s chi-square test. When p-value <0.05 was reported, results
were identified as significant.
INSTITUTIONAL BOARD APPROVAL
This project was approved by the Ethics Committee on Human
Research-Federal University of Minas Gerais, Belo Horizonte,
Brazil. Written informed consent was obtained from the parents
of patients enrolled in the study.
RESULTS
The mean age at the first acute episode was 9.1± 4.1 years. The
distribution patients by gender was similar (F: 50.4% M: 49.6%),
except for those with Sydenham chorea (F/M= 1.6; p: 0.0013). In
the distribution of patients according to the Jones criteria, carditis
(66.2%) and polyarthritis (70.4%), isolated or combined, were the
major manifestations most commonly observed.
As regards the type and site of valvular lesions in the chronic
phase, valvular regurgitation was present in 72.9% and mixed
lesions in 27.1% of patients. The mitral valve was the most affected.
Isolated mitral dysfunction or in association with other valvar
lesions were seen in 98.2% of patients and almost a half of patients
(44.2%) presented isolated mitral regurgitation. Aortic regurgita-
tion was found in 37.8% and most often seen concurrently with
an affected mitral valve. No patients with aortic stenosis or iso-
lated mitral stenosis were seen. Complete regression of the valvular
lesions at echocardiographic interrogation was observed in 34.4%
of the patients, mostly presenting a mild dysfunction. Carditis
was diagnosed in 465 patients and classified as severe in 39.8%,
moderate in 28.6%, and mild in 31.6%.
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According to the past history and before being admitted to the
hospital, 34.6% of children and adolescents had presented recur-
rences, 22.2% had one, and 12.4% had two or more subsequent
episodes. After admission, the recurrence rate per patient-year was
0.058, which means that out of a total of 85 recurrent episodes,
51/238 (21.4%) occurred during the first period of investigation
and 34/454 (7.5%) during the second one.
When the entire patient population was considered, a higher
prevalence of significant carditis (p: 0.000) and more severe valvar
sequels (p: 0.000) were seen in patients with recurrences (Tables 1
and 2).
The comparative analysis of the two periods of investigation
showed that the clinical profile of the acute phase, first episodes or
subsequent attacks, was unchanged regarding the age at the pri-
mary attack, gender, frequency, and site of affected joints, besides
the most frequent association of valvular lesions (Table 3). How-
ever, after the decrease in the frequency of recurrences, which
followed the improvement of the delivery and adherence to sec-
ondary prophylaxis, important modifications in the severity of
the disease were observed during the follow-up. A decrease in
the frequency of severe carditis, stenotic valvular lesions, hospital
admissions, surgical approach, and deaths was noticed showing
significant differences in all indices between the two periods of
investigation (Table 4).
DISCUSSION
The present study confirms previous results of frequent involve-
ment of the heart in children and adolescents with RF and the
influence of recurrences in the severity of valvular sequels (5).
The more patients are faced with recurrent episodes, the more
advanced disease and its complications can be anticipated in the
chronic phase (4). This poor outcome was seen prior to the imple-
mentation of prophylactic measures and was represented by a
higher demand for hospitalization and surgery besides a higher
number of deaths. Similarly, a prevalence of mitral stenosis three
times higher than that presented after the control of recurrences
was found, showing a shorter and unexpected time course for this
age group. This accelerated progression into severe forms con-
trasts with the most often latent period of 20–40 years between
the presentation of the obstructive lesion and the episode of
RF. This trend has already been reported and may reflect the
final result of multiple insults (17, 22). At the other end of the
spectrum, we highlight the potential regression of less signifi-
cant valvular regurgitation. The involution of valvular disease
at echocardiographic interrogation observed in 34.3% of chil-
dren and adolescents in the present investigation reinforces the
need for a timely identification of patients at an early stage of
the illness. Patients with mild valvular dysfunction and submit-
ted to regular secondary prophylaxis have shown a good prog-
nosis without detectable disease after 10 years (23, 24). A bet-
ter cardiac condition at the time of the initial attack has also
been pointed out as a factor related to improvement of mitral
regurgitation (25). In this setting, the routine echocardiographic
screening for all patients included in the program, even for sus-
pect cases without clinical evidence of valvar dysfunction, con-
tributed to an early identification of mild dysfunctions, clinical or
subclinical.














Yes 141 (30.3) 69 (57.1) 210 (35.9) 0.000 3.093 1.727–
5.540
No 324 (69.7) 51 (42.9) 375 (64.1)
Total n (%) 465 (100) 120 (100) 585 (100)














Yes 98 (40.4) 47 (10.2) 145 (20.2) 0.000 3.000 1.697–
5.302
No 144 (59.7) 413 (89.8) 557 (79.4)
Total n (%) 242 (100) 460 (100) 702 (100)
As expected, significant degrees of carditis were more frequently
seen in patients during subsequent attacks when compared with
those at primary episodes. In the comparative analysis, the con-
trol of recurrences was followed by a decrease in the frequency of
severe carditis from 49.8 to 30.1% and an increase of mild carditis
from 19.6 to 43.2%. Additionally, the prevalence of severe cardiac
involvement observed after the decrease of recurrences (30.1%)
was similar to the percentual found in all patients at a primary
attack (30.3%). These findings can be related to a timely diagnosis
and the more effective measures to prevent the progression of the
cardiac damage mainly in patients at the initial episode, where less
significant degrees of carditis are expected.
In countries such Brazil, programs to implement the delivery of
secondary prophylaxis have been recommended as a priority for
RHD control (26, 27). This approach has shown to be cost-effective
at population and community levels (26–28). When compared to
primary prevention, this RHD control strategy is targeted at a
small and specific populational group, and can be integrated into
the existing healthcare system. It has been estimated that pro-
grams to improve secondary prophylaxis cost less than half the
amount spent on tertiary prevention and less than one-seventh
of that spent on primary prevention (29). The control program
at UFMG has required a multi-faceted approach including con-
tinuous surveillance, and according to our observations, no single
measure could be exclusively related to the outcomes. Previous
divulgation by the media and the incorporation of activities into
the existing health system infrastructure supported the training of
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Table 3 | Comparative analysis of the clinical profile of presentation.
Clinical profile Time interval p OR CI
07/77–07/88 (n = 248) 08/88–02/00 (n = 454)
Age at primary episode (years) (mean±DP/median) 8.8±5.5/8.8 9.4±3.1/9.0 0.0823
Gender (F/M) 1.2 1.01 0.9090 1.041 0.598–1.812
Large/small joints (%) 86.7/13.3 84.5/15.3 0.3548 1.084 0.744–1.580
ΣMR, MR+AR, AR+MR+MS, MR+MS /other associations (%) 94.2/5.8 95.6/4.4 0.3637 1.532 0.419–5.603
MS, mitral stenosis; MR, mitral regurgitation; AR, aortic regurgitation.
Table 4 | Comparative analysis of frequency of recurrences and indices of severity.
Indices of severity Time interval p OR CI
07/77–07/88 (n = 248) 08/88–02/00 (n = 454)
Recurrences 22.4 7.4 0.0000 2.163 1.222–4.169
Severe/mild carditis 49.8/19.6 30.1/43.2 0.0000 1.556 1.129–2.144
Frequency of MS*/MR and/or AR 33.2/66.8 11.9/88.1 0.0000 2.129 1.287–3.523
Hospitalization 45.4 28.4 0.0000 1.478 1.065–2.052
Surgeries 13.3 1.5 0.0000 3.973 1.860–14.539
Deaths 5.4 0.4 0.0000 3.591 1.582–22.156
MS, mitral stenosis; MR, mitral regurgitation; AR, aortic regurgitation, *associated with MR and/or AR.
healthcare providers, which was followed by the establishment of
the Reference Center and the implementation of activities. Appro-
priate delivery of reliable forms of benzathine penicillin and the
development of strategies to promote the adherence to prophy-
lactic regimens were crucial to reach our goals. In this setting, we
highlight the introduction of the prophylaxis card to control the
compliance of patients and the combined actions of the multidis-
ciplinary health team in providing information and improving the
clinical assistance and relationship with patients and their families.
Considering the necessity of a continuous surveillance, the bet-
ter adherence to a regular follow-up allowed the monitoring of
the clinical evolution at least twice a year. It also contributed
to reinforce the commitment to the use of medication besides
improving communication with the referring healthcare centers.
Special attention was given to adolescents. This age group was
less likely to show adequate compliance to penicillin injections. As
regards the ongoing debate about the interval between the doses
of intramuscular benzathine penicillin for the implementation of
the secondary prophylaxis, whether it should happen every 3 or
4 weeks (24, 30), our view is that the approach must be tailored
to the epidemiological context. Our choice of the three weekly
regimens took into account the frequency of the disease and the
individual risks of exposure to group A streptococcus.
Although important modifications in the morbimortality
indices were found in the present investigation and had already
been observed in other RHD control programs, there is a clear
necessity of increasing our understanding of this preventable and
baffling disease, which continues to challenge clinicians and the
scientific community. Moving forward, efforts must be directed
toward research. In prospect, our more promising advances
include the availability of a streptococcal vaccine for an effective
access to primary prevention (31). As it has been pointed out by
Carapetis and Zühlke in the discussion about the priorities for the
global research in RF and RHD, “the major challenge, however, is
not to miss the very real opportunity that now exists to translate
current and future research into concrete action” (32). As a result,
informed decision can be made and strategies can be defined for
intervention at the individual and public health levels.
In conclusion, the results of this investigation showed that the
cardiac involvement in RF remains frequent as does the association
of recurrences with significant valvar dysfunction. In the scenario
of the substantial burden imposed by the disease and poor long-
term outcomes, the implementation of a program of secondary
prophylaxis is an effective strategy to prevent recurrent RF and
progression of RHD.
LIMITATIONS OF THE STUDY
This study has limitations as the data were collected retrospec-
tively and the investigated databases and medical reports cannot
be proved to be either complete or comprehensive. In addition,
the quality of the Doppler echocardiographic approach and con-
sequently the diagnosis accuracy of valvar lesions were not lin-
ear as technology has improved throughout the long period of
investigation as regards the methods and quality of the equipment.
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